Reported Earnings • Apr 24
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: CN¥1.13 (up from CN¥0.96 in FY 2024). Revenue: CN¥2.88b (up 27% from FY 2024). Net income: CN¥239.8m (up 19% from FY 2024). Profit margin: 8.3% (down from 8.9% in FY 2024). Revenue exceeded analyst estimates by 4.7%. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
Shanghai Haoyuan Chemexpress Co., Ltd., Annual General Meeting, May 28, 2026 Shanghai Haoyuan Chemexpress Co., Ltd., Annual General Meeting, May 28, 2026, at 14:00 China Standard Time. Location: Building 3, Lane 1999, Zhangheng Road, Pudong New Area, Shanghai China Announcement • Mar 30
Shanghai Haoyuan Chemexpress Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 02
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: CN¥1.17 (up from CN¥0.96 in FY 2024). Revenue: CN¥2.87b (up 26% from FY 2024). Net income: CN¥247.8m (up 23% from FY 2024). Profit margin: 8.6% (down from 8.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥69.30, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 42x in the Life Sciences industry in China. Total returns to shareholders of 7.5% over the past three years. Announcement • Dec 26
Shanghai Haoyuan Chemexpress Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥74.63, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 38x in the Life Sciences industry in China. Total returns to shareholders of 23% over the past three years. Announcement • Sep 30
Shanghai Haoyuan Chemexpress Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥78.28, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 39x in the Life Sciences industry in China. Total returns to shareholders of 25% over the past three years. Reported Earnings • Aug 31
Second quarter 2025 earnings released: EPS: CN¥0.42 (vs CN¥0.25 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.42 (up from CN¥0.25 in 2Q 2024). Revenue: CN¥704.8m (up 28% from 2Q 2024). Net income: CN¥89.4m (up 67% from 2Q 2024). Profit margin: 13% (up from 9.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥68.48, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 36x in the Life Sciences industry in China. Total loss to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥51.89, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 34x in the Life Sciences industry in China. Total loss to shareholders of 39% over the past three years. Announcement • Jun 30
Shanghai Haoyuan Chemexpress Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥44.10, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 30x in the Life Sciences industry in China. Total loss to shareholders of 28% over the past three years. New Risk • May 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • May 02
First quarter 2025 earnings released: EPS: CN¥0.30 (vs CN¥0.079 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.30 (up from CN¥0.079 in 1Q 2024). Revenue: CN¥606.1m (up 20% from 1Q 2024). Net income: CN¥62.4m (up 272% from 1Q 2024). Profit margin: 10% (up from 3.3% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 7% per year. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥34.55, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 29x in the Life Sciences industry in China. Total loss to shareholders of 34% over the past three years. Reported Earnings • Mar 03
Full year 2024 earnings released: EPS: CN¥0.97 (vs CN¥0.61 in FY 2023) Full year 2024 results: EPS: CN¥0.97 (up from CN¥0.61 in FY 2023). Revenue: CN¥2.26b (up 20% from FY 2023). Net income: CN¥205.0m (up 61% from FY 2023). Profit margin: 9.1% (up from 6.8% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Dec 27
Shanghai Haoyuan Chemexpress Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025 Price Target Changed • Nov 08
Price target increased by 59% to CN¥51.00 Up from CN¥32.00, the current price target is provided by 1 analyst. New target price is 16% above last closing price of CN¥43.78. Stock is down 8.7% over the past year. The company is forecast to post earnings per share of CN¥0.79 for next year compared to CN¥0.61 last year. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to CN¥45.50, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 23x in the Life Sciences industry in China. Total loss to shareholders of 57% over the past three years. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥31.80, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 73% over the past three years. Announcement • Sep 30
Shanghai Haoyuan Chemexpress Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥27.94, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 21x in the Life Sciences industry in China. Total loss to shareholders of 79% over the past three years. New Risk • Sep 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.0% net profit margin). Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.23 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.25 (up from CN¥0.23 in 2Q 2023). Revenue: CN¥550.7m (up 19% from 2Q 2023). Net income: CN¥53.7m (up 10% from 2Q 2023). Profit margin: 9.7% (in line with 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥22.33, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Life Sciences industry in China. Total loss to shareholders of 81% over the past three years. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥23.18, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 19x in the Life Sciences industry in China. Total loss to shareholders of 82% over the past three years. New Risk • Jul 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (5.0% net profit margin). Announcement • Jun 29
Shanghai Haoyuan Chemexpress Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Reported Earnings • Apr 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.85 (down from CN¥1.33 in FY 2022). Revenue: CN¥1.88b (up 38% from FY 2022). Net income: CN¥127.4m (down 34% from FY 2022). Profit margin: 6.8% (down from 14% in FY 2022). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 52%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Life Sciences industry in China. Announcement • Apr 26
Shanghai Haoyuan Chemexpress Co., Ltd., Annual General Meeting, May 17, 2024 Shanghai Haoyuan Chemexpress Co., Ltd., Annual General Meeting, May 17, 2024, at 13:00 China Standard Time. Location: Building 3, Lane 1999, Zhangheng Road, Pudong New Area, Shanghai China Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥28.81, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 23x in the Life Sciences industry in China. Total loss to shareholders of 67% over the past year. Announcement • Mar 29
Shanghai Haoyuan Chemexpress Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥41.70, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 46% over the past year. Reported Earnings • Feb 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.81 (down from CN¥1.33 in FY 2022). Revenue: CN¥1.88b (up 38% from FY 2022). Net income: CN¥121.1m (down 37% from FY 2022). Profit margin: 6.4% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 52%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in China. New Risk • Feb 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (8.7% net profit margin). Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥33.36, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 21x in the Life Sciences industry in China. Total loss to shareholders of 63% over the past year. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥52.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 25x in the Life Sciences industry in China. Total loss to shareholders of 31% over the past year. Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.29 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.16 (down from CN¥0.29 in 3Q 2022). Revenue: CN¥495.2m (up 42% from 3Q 2022). Net income: CN¥23.3m (down 44% from 3Q 2022). Profit margin: 4.7% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.37 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.32 (down from CN¥0.37 in 2Q 2022). Revenue: CN¥462.6m (up 44% from 2Q 2022). Net income: CN¥48.6m (down 10.0% from 2Q 2022). Profit margin: 11% (down from 17% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in China. Announcement • Jun 28
Shanghai Haoyuan Chemexpress Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Shanghai Haoyuan Chemexpress Co., Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Apr 29
First quarter 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.60 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.43 (down from CN¥0.60 in 1Q 2022). Revenue: CN¥418.4m (up 40% from 1Q 2022). Net income: CN¥46.2m (down 26% from 1Q 2022). Profit margin: 11% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China. Reported Earnings • Feb 28
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥1.86. Revenue: CN¥1.36b (up 40% from FY 2021). Net income: CN¥193.6m (up 1.4% from FY 2021). Profit margin: 14% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Life Sciences industry in China. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Yao Gao was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.47 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.40 (down from CN¥0.47 in 3Q 2021). Revenue: CN¥348.9m (up 45% from 3Q 2021). Net income: CN¥41.5m (down 15% from 3Q 2021). Profit margin: 12% (down from 20% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥97.95, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 29x in the Life Sciences industry in China. Total loss to shareholders of 60% over the past year. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.52 (vs CN¥0.53 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.52. Revenue: CN¥321.3m (up 40% from 2Q 2021). Net income: CN¥54.0m (up 32% from 2Q 2021). Profit margin: 17% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 53%, compared to a 39% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥180, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 43x in the Life Sciences industry in China. Total loss to shareholders of 48% over the past year. Reported Earnings • Apr 27
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥2.94 (up from CN¥2.30 in FY 2020). Revenue: CN¥969.2m (up 53% from FY 2020). Net income: CN¥191.0m (up 49% from FY 2020). Profit margin: 20% (in line with FY 2020). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 53%, compared to a 42% growth forecast for the pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥184, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 41x in the Life Sciences industry in China. Reported Earnings • Feb 27
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥2.93 (up from CN¥2.30 in FY 2020). Revenue: CN¥967.2m (up 52% from FY 2020). Net income: CN¥190.5m (up 48% from FY 2020). Profit margin: 20% (in line with FY 2020). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 41%, compared to a 50% growth forecast for the pharmaceuticals industry in China.